ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

被引：0

作者：

Bronowicki, J-P ^{[1
]}

Pol, S. ^{[2
]}

Thuluvath, P. ^{[3
]}

Larrey, D. ^{[4
]}

Martorell, C. T. ^{[5
]}

Rustgi, V. K. ^{[6
]}

Morris, D. W. ^{[7
]}

Younes, Z. ^{[8
]}

Fried, M. W. ^{[9
]}

Bourliere, M. ^{[10
]}

Hezode, C. ^{[11
]}

Reddy, R. ^{[12
]}

Massoud, O. ^{[13
]}

Abrams, G. A. ^{[14
]}

Ratziu, V. ^{[15
]}

He, B. ^{[16
]}

Eley, T. ^{[16
]}

Ahmad, A. ^{[16
]}

Thiry, A. ^{[16
]}

Llamoso, C. ^{[16
]}

Mendez, P. ^{[16
]}

Hughes, E. ^{[16
]}

机构：

[1] Hop Adultes Brabois, Serv Hepatogastroenterol, Vandoeuvre Les Nancy, France

[2] Hop Cochin, Serv Hepatol Adulte, F-75674 Paris, France

[3] Mercy Med Ctr, Baltimore, MD USA

[4] Hop St Eloi, Serv Hepatogastroenterol & Transplantat, Montpellier, France

[5] Res Inst, Springfield, MA USA

[6] Metropolitan Res, Fairfax, VA USA

[7] Healthcare Res Consultants, Tulsa, OK USA

[8] Gastro One, Germantown, TN USA

[9] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA

[10] Hop St Joseph, Serv Hepatogastroenterol, Marseille, France

[11] CHU Henri Mondor, Serv Hepatogastroenterol, F-94010 Creteil, France

[12] Hosp Univ Penn, Philadelphia, PA 19104 USA

[13] Univ Alabama Birmingham, Birmingham, AL USA

[14] Alabama Liver & Digest Specialists, Montgomery, AL USA

[15] Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, F-75634 Paris, France

[16] Bristol Myers Squibb Co, Clin Res & Dev, Princeton, NJ USA

来源：

JOURNAL OF HEPATOLOGY | 2012年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1096

引用

下载

页码：S431 / S432

页数：2

共 50 条

[21] COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION
Everson, G. T.
Di Bisceglie, A. M.
Vierling, J. M.
Hsieh, F.
Trenkle, J. D.
Kanwar, B.
Subramanian, M.
McHutchison, J. G.
Ghalib, R. H.
Rustgi, V. K.
Kwo, P. Y.
JOURNAL OF HEPATOLOGY, 2013, 58 : S6 - S6
[22] INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
Everson, G. T.
Sims, K. D.
Rodriguez-Torres, M.
Hezode, C.
Lawitz, E.
Bourliere, M.
Loustaud-Ratti, V.
Rustgi, V.
Schwartz, H.
Tatum, H.
Marcellin, P.
Pol, S.
Thuluvath, P. J.
Eley, T.
Wang, X.
Huang, S. -P.
McPhee, F.
Wind-Rotolo, M.
Chung, E.
Pasquinelli, C.
Grasela, D. M.
Gardiner, D. F.
JOURNAL OF HEPATOLOGY, 2013, 58 : S573 - S573
[23] Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naive or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gane, Edward J.
Schwabe, Christian
Hyland, Robert H.
Yang, Yin
Svarovskaia, Evguenia
Stamm, Luisa M.
Brainard, Diana M.
McHutchison, John G.
Stedman, Catherine A.
GASTROENTEROLOGY, 2016, 151 (03) : 448 - +
[24] Interim analysis of an interferon (INF)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients
Everson, G. T.
Sims, K. D.
Rodriguez-Torres, M.
Hezode, C.
Lawitz, E.
Bourliere, M.
Loustaud-Ratti, V.
Rustgi, V.
Schwartz, H.
Tatum, H.
Marcellin, P.
Pol, S.
Thuluvath, P. J.
Eley, T.
Wang, X.
Huang, S. P.
Mcphee, F.
Wind-Rotolo, M.
Chung, E.
Pasquinelli, C.
Grasela, D. M.
Gardiner, D. F.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 154 - 154
[25] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)
Kwo, P. Y.
Lawitz, E. J.
McCone, J.
LANCET, 2010, 376 (9748): : 1224 - 1224
[26] Daclatasvir plus asunaprevir in treatment-naive patients with hepatitis C virus genotype 1b infection
Wei, Lai
Wang, Fu-Sheng
Zhang, Ming-Xiang
Jia, Ji-Dong
Yakovlev, Alexey A.
Xie, Wen
Burnevich, Eduard
Niu, Jun-Qi
Jung, Yong Jin
Jiang, Xiang-Jun
Xu, Min
Chen, Xin-Yue
Xie, Qing
Li, Jun
Hou, Jin-Lin
Tang, Hong
Dou, Xiao-Guang
Gandhi, Yash
Hu, Wen-Hua
McPhee, Fiona
Noviello, Stephanie
Treitel, Michelle
Mo, Ling
Deng, Jun
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (12) : 1361 - 1372
[27] Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection
Kwo, Paul Y.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (03) : 179 - 188
[28] ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS
Pol, S.
Jablkowski, M.
Trenkle, J. D.
Kanwar, B.
Bekele, B. N.
Subramanian, M.
McHutchison, J. G.
Flamm, S. L.
Muir, A. J.
JOURNAL OF HEPATOLOGY, 2013, 58 : S31 - S31
[29] DUAL ORAL COMBINATION THERAPY WITH THE NS5A INHIBITOR BMS-790052 AND THE NS3 PROTEASE INHIBITOR BMS-650032 ACHIEVED 90% SUSTAINED VIROLOGIC RESPONSE (SVR12) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS
Chayama, Kazuaki
Takahashi, Shoichi
Kawakami, Yoshiiku
Ikeda, Kenji
Suzuki, Fumitaka
Toyota, Joji
Karino, Yoshiyasu
Ohmura, Takumi
Ishikawa, Hiroki
Watanabe, Hideaki
Guo, Tong
McPhee, Fiona
Hughes, Eric A.
Kumada, Hiromitsu
HEPATOLOGY, 2011, 54 : 1428A - 1428A
[30] EFFICACY OF PEGINTERFERON ALPHA-2A AND RIBAVIRIN COMBINATION THERAPY IN TREATMENT-NAIVE ESTONIAN PATIENTS WITH CHRONIC HEPATITIS C
Brjalin, Vadim
Salupere, Riina
Tallo, Tatjana
Kuznetsova, Tatiana
Priimaegi, Ljudmilla
Tefanova, Valentina
CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2012, 20 (02) : 150 - 155

← 1 2 3 4 5 →